x
ServiziMenu principaleHome
Print
Home > Pubblicazioni > Pubblicazioni > 2001-2010

Pubblicazioni dal 2001 al 2010

  • Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C.
    Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
    Cancer Immunol Immunother 59: 553–561, 2010 (IF=3.791)
  • Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, and Perrone F. Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
    Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study.
    J Clin Oncol 28 (10): 1645-51, 2010 (IF=17.793)
  • Buti S, Lazzarelli S, Chiesa MD, Simonelli C, Lo Re G, Lheshi A, Simon S, Mattioli R, Caminiti C, Mazza G, Donini M, Passalacqua R; from the GOIRC (Italian Oncology Group for Clinical Research).
    Dose-finding Trial of a Combined Regimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study.
    J Immunother 33 (7): 735-41, 2010 (IF=3.203)
  • Giorgio Cocconi, Caterina Caminiti, Giovanni Zaninetta, Rodolfo Passalacqua, Stefano Cascinu, Francesco Campione, Renata Todeschini, Sergio Zani, Tiberio d’Aloia and Luigi Migone
    National survey of medical choices in caring for terminally ill patients in Italy, a cross-sectional study
    Tumori, 96: 122-130, 2010
  • Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; On behalf of Italian Oncology Group for Cancer Research.
    Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC.
    J Natl Cancer Inst 100 (6): 388-398, 2008. (IF=14.069)
  • Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study.
    Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
    Lancet 369 (9561): 559-70, 2007; Erratum in: Lancet 369 (9565): 906, 2007. (IF=30.758)
  • Dalla Chiesa M, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tommasello G, Cocconi G; Italian Oncology Group for Clinical Research.
    Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.
    Acta Biomed 78 (3): 204-209, 2007
  • Di Costanzo F, Gasperoni S, Papaldo P, Bilancia D, Manzione L, Landucci E, Mazzoni F, Cognetti F.
    Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
    Annals of Oncology 17 (1): 79-84, 2006 (IF=5.647)
  • Sobrero A, Frassineti G, Falcone A, Dogliotti L, Rosso R, Di Costanzo F, Bruzzi P; INTACC.
    Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
    British Journal of Cancer 92 (1): 24-29, 2005.; errata corrige in Br J Cancer. 93: 733, 2005 (IF=4.346)
  • Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P, Gasperoni S.
    Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian Oncology Group for Clinical Research (GOIRC).
    British Journal of Cancer 93 (2): 185-189, 2005. (IF=4.346)
  • G. Cocconi, B. Di Blasio, C. Boni, G. Bisagni, E. Rondini, M. A. Bella, F. Leonardi, L. Savoldi, C. Vallisneri, R. Camisa, P. Bruzzi, on behalf of the Italian Oncology Group for Clinical Research (GOIRC).
    Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term.
    Annals of Oncology 16: 1469-1476, 2005 (IF=5.647)
  • Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research.
    HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
    Clin Breast Cancer. 6(3): 253-9, 2005. (IF=2.065)
  • Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo C.
    Cost of insurance policies for investigator-initiated cancer clinical trials in Italy
    Tumori 91 (4): 373-373, 2005 (IF=0.863)
  • RC Coombes, E Hall, LJ Gibson, M Phil, R Paridaens, J Jassem, T Delozier, SE Jones, I Alvarez, G Bertelli, O Ortmann, AS Coates, E Bajetta, D Dodwell, RE Coleman, LJ Fallowfield, E Mickiewicz, J Andersen, PE Lonning, G Cocconi, A Stewart, N Stuart, CF Snowdon, M Carpentieri, G Massimini, JM Bliss for the Intergroup Exemestane Study.
    A randomized trial of Exemestane after two to three years of Tamoxifen therapy in postmenopausal women with primary brest cancer.
    N Engl J Med 350: 1081-1092, 2004. (IF=47.050)
  • Di Costanzo F, Manzione L, Gasperoni S, Bilancia D, Acito L, Angiona S, Mazzoni F, Giustini L; Italian Oncology Group for Cancer Research.
    Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.
    Cancer Invest. 22 (3): 331-337, 2004. (IF=2.105)
  • Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo C.
    Insurance for independent cancer trials.
    Annals of Oncology 15 (11):1722-1723, 2004. (IF=5.647)
  • Cocconi G., Passalacqua R., Foladore S., Carlini P., Acito L., Maiello E., Marchi M., Gebbia V., Di Sarra S., Beretta M., Bacchi M.
    Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
    Melanoma Research 13: 73-79, 2003. (IF=2.061)
  • G. Cocconi, P. Carlini, A. Gamboni, S. Gasperoni, C. Rodinò, S. Zironi, G. Bisagni, S. Porrozzi, F. Cognetti, F. Di Costanzo, R. Canaletti, E. M. Ruggeri, R. Camisa, F. Pucci.
    Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
    Annals of Oncology 14: 1258-1263, 2003. (IF=5.647)
  • G. Cocconi.
    Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimens.
    Breast Cancer Research and Treatment 80: 313-320, 2003. (IF=4.696)
  • Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A, Lionetto R, Bruzzi P, Luppi G, Gallo L, Conte P, Comandone A, Turci D, Marzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M, Rosso R; Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
    Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
    Annals of Oncology 14:1365-72, 2003. (IF=5.647)
  • Zeuli M., Di Costanzo F., Sdrobolini A., Gasperoni S., Paoloni F.P., Carpi A., Moscetti L., Cherubini R., Cognetti F. on behalf of Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC) e Gruppo Oncologico Laziale (GOL).
    Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
    Annals of Oncology 12: 1737-1741, 2001 (IF=5.647)
  • Cocconi G., Di Blasio B., Boni C., Bisagni G., Ceci G., Rondini E., Bella M., Leonardi F., Savoldi L., Camisa R., Bruzzi P.
    Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cancer 95: 228-235, 2002. (IF=5.418)
  • Colozza M., Bisagni G., Mosconi A. M., Gori S., Boni C., Sabbatini R., Frassoldati A., Passalacqua R., Rosa Bian A., Rodinò C., Rondini E., Algeri R., Di Sarra S., De Angelis V., Cocconi G., Tonato M., on behalf of the Italian Oncology Group for Clinical Research (GOIRC).
    Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.
    European Journal of Cancer 38: 2279-2288, 2002. (IF=4.121).
  • Zeuli M., Pino M.S., Cognetti F.
    La capecitabina nel trattamento del carcinoma colorettale.
    Tumori 87 (1 suppl. 1): 55-56, 2001. (IF=0.863)